Weight loss drugs such as Ozempic can potentially lower the risk of Alzheimer's disease

Question

According to a recent study "Patients prescribed semaglutide had a 40% to 70% reduced risk of first-time Alzheimer’s diagnosis, compared to other antidiabetic medications."

Comments

You bring up an interesting point regarding the potential connection between semaglutide, the active ingredient in Ozempic, and reduced Alzheimer's risk. However, it's essential to critically evaluate the study you referenced. While a 40% to 70% reduction in risk sounds promising, it's crucial to consider the study's design, sample size, and whether it has been peer-reviewed. For example, was this a randomized controlled trial, or an observational study? These factors significantly affect the validity of the findings.

---

I think this is an interesting topic. I looked more into it and The findings suggest that the benefits of semaglutide might extend beyond glycemic control and weight loss, potentially offering neuroprotective effects as well. However, it is important to note that while these results are compelling, they stem from observational data rather than controlled clinical trials, which are essential for establishing causation​.

---

This claim is very intriguing, but its important to know whether the data in the study is from scientific tests and results, or mere observation. Ask yourself: "Where did this info come from? and "What is the reason behind the results?"

Answer 1

This article is backed up with credible source information. Multiple other news articles have also picked up the same story having similar findings as this article from the Fortune. The Journal that they reference for their statistics, the Alzheimer's & Dementia: The Journal of the Alzheimer's Association provided their own study on the topics with relevant data to back up their claims. Their claim is more so that diabetes in general leads to more health issues including  Alzheimer's so their the more people lose weight the better.

Answer 2

The claim overall seems to be supported by current research, despite sounding a bit exaggerated. The article doesn't seem to assert any causal claims that were not made in the original research by The Journal of the Alzheimer's Association. The study concluded that there was a relationship between semaglutide and a decreased risk of Alzheimer's Disease which was relayed in the article without using information that has yet to be proven. The journal which the study has been published in does not appear to be very large, but also does not have a negative reputation, meaning there is still room for skepticism regarding this study, but no reason to currently doubt it's validity.